2269 N 주식 개요 An investment holding company, provides end-to-end solutions and services for biologics discovery, development, and manufacturing for biologics industry in the People’s Republic of China, North America, Europe, Singapore, Japan, South Korea, and Australia. 자세한 내용
{"enabled":false,"variant":{"name":"disabled","enabled":false},"ready":false,"error":null}
생각, 링크 및 회사 내러티브를 캡처하세요.
WuXi Biologics (Cayman) Inc. 경쟁사 가격 내역 및 성능
다음에 대한 주가 최고가, 최저가 및 변동 요약 WuXi Biologics (Cayman) 과거 주가 현재 주가 HK$62.53 52주 최고치 HK$62.53 52주 최저치 HK$62.53 베타 0.66 1개월 변경 0% 3개월 변경 사항 n/a 1년 변경 사항 n/a 3년 변화 -74.45% 5년 변화 n/a IPO 이후 변화 -73.63%
최근 뉴스 및 업데이트
WuXi Biologics (Cayman) Inc. (SEHK:2269) completed the acquisition of remaining 30% stake in WuXi Vaccines (Cayman) Inc. from Shanghai Hile Bio-Technology Co., Ltd. (SHSE:603718). Oct 25
WuXi Reportedly Explores Sale of Pharma Units as US Restrictions Loom Oct 05
WuXi Biologics Successfully Completes First Scale-Up of High-Productivity Bioprocessing Platform WuXiUI in 2,000L GMP Manufacturing Aug 30
WuXi Biologics (Cayman) Inc. to Report First Half, 2024 Results on Aug 21, 2024 Jul 25
Wuxi Biologics (Cayman) Inc. Announces Retirement of Weichang Zhou as Chief Technology Officer and President of Global Biologics Development and Operations and Re-Designates as Non-Executive Director and Honorary President of Global Biologics Development and Operations and Senior Advisor to Chief Executive Officer Apr 03
WuXi Biologics (Cayman) Inc., Annual General Meeting, Jun 19, 2024 Mar 27 더 많은 업데이트 보기
WuXi Biologics (Cayman) Inc. (SEHK:2269) completed the acquisition of remaining 30% stake in WuXi Vaccines (Cayman) Inc. from Shanghai Hile Bio-Technology Co., Ltd. (SHSE:603718). Oct 25
WuXi Reportedly Explores Sale of Pharma Units as US Restrictions Loom Oct 05
WuXi Biologics Successfully Completes First Scale-Up of High-Productivity Bioprocessing Platform WuXiUI in 2,000L GMP Manufacturing Aug 30
WuXi Biologics (Cayman) Inc. to Report First Half, 2024 Results on Aug 21, 2024 Jul 25
Wuxi Biologics (Cayman) Inc. Announces Retirement of Weichang Zhou as Chief Technology Officer and President of Global Biologics Development and Operations and Re-Designates as Non-Executive Director and Honorary President of Global Biologics Development and Operations and Senior Advisor to Chief Executive Officer Apr 03
WuXi Biologics (Cayman) Inc., Annual General Meeting, Jun 19, 2024 Mar 27
WuXi Biologics (Cayman) Inc.(SEHK:2269) dropped from S&P Global 1200 Mar 19 WuXi Biologics (Cayman) Inc.(SEHK:2269) dropped from S&P International 700
WuXi Biologics (Cayman) Inc. to Report Q4, 2023 Results on Mar 26, 2024 Feb 15
WuXi Biologics Successfully Completes First 1,6000L Manufacturing Run in Ireland Feb 01
WuXi Biologics Launches WuXia ADCC PLUS™ for the Development and Manufacturing of Afucosylated Antibodies that Elicit Enhanced ADCC Effect Jan 25
WuXi Biologics Receives U.S. Patent for Proprietary Bispecific Antibody Technology Platform WuXiBody™ Jan 17
WuXi Biologics (Cayman) Inc. Announces Executive Changes, Effective March 31, 2024 Jan 16
Less than half of directors are independent Dec 22
WuXi Biologics (Cayman) Inc. (SEHK:2269) commences an Equity Buyback Plan for 424,841,177 shares, representing 10% of its issued share capital, under the authorization approved on June 27, 2023. Dec 08
Wuxi Biologics Successfully Implements Fully Integrated Continuous Process with Breakthrough Productivity of 6 g/L/Day At Pilot Scale Nov 22
WuXi Biologics Launches New High-Productivity Bioprocessing Platform WuXiUI™ for Cost-Effective Commercial Manufacturing and Desirable Product Quality Oct 17
Wuxi Biologics (Cayman) Inc. Announces Executive Changes Aug 17
WuXi Biologics (Cayman) Inc. to Report First Half, 2023 Results on Aug 23, 2023 Jul 26 WuXi Biologics (Cayman) Inc., Annual General Meeting, Jun 15, 2023 May 25
WuXi Biologics (Cayman) Inc. Announces Demise of Ning Zhao, Non-Executive Director, Member of Remuneration Committee and Member of Environmental, Social and Governance Committee May 18
WuXi Biologics (Cayman) Inc. Announces Board and Board Committee Changes May 09
Investor sentiment deteriorates as stock falls 26% Feb 23
Less than half of directors are independent Feb 23 WuXi Biologics (Cayman) Inc. to Report Fiscal Year 2022 Results on Mar 22, 2023
Less than half of directors are independent Jan 31
WuXi Biologics (Cayman) Inc. Announces Demise of Teh-Ming Walter Kwauk, Independent Non-Executive Director, the Chairman of the Audit Committee of the Company and A Member of the Nomination Committee of the Company Nov 26
Wuxi Biologics (Cayman) Inc. Announces Appointments to Strategy Committee Nov 24
WuXi Biologics (Cayman) Inc. (SEHK:2269) commences an Equity Buyback Plan for 425,926,547 shares, representing 10% of its issued share capital, under the authorization approved on June 10, 2022. Oct 01
First half 2022 earnings released: EPS: CN¥0.61 (vs CN¥0.44 in 1H 2021) Sep 24
WuXi Biologics (Cayman) Inc. Receives Regulatory Approvals for Drug Substance and Drug Product Facilities from U.S. FDA and EMA Sep 20
Investor sentiment deteriorated over the past week Sep 19
Less than half of directors are independent Sep 19
First half 2022 earnings released: EPS: CN¥0.61 (vs CN¥0.44 in 1H 2021) Aug 18
Less than half of directors are independent Aug 18
WuXi Biologics (Cayman) Inc. Appoints Weichang Zhou as Member of the Strategy Committee Aug 18 WuXi Biologics (Cayman) Inc. Provides Earnings Guidance for the Six Months Ended June 30, 2022
Less than half of directors are independent Jul 18
CEO & Executive Director recently sold Mex$45m worth of stock Jun 17
Investor sentiment improved over the past week Jun 13
Less than half of directors are independent May 30
Less than half of directors are independent Feb 12 Wuxi Biologics (Cayman) Inc. Provides Unaudited Consolidated Earnings Guidance for the Ended December 31, 2021
WuXi Biologics Announces Completion of GMP Production At 24,000L Line of Its Drug Substance Facility MFG5 Nov 24
CEO & Executive Director recently bought Mex$102m worth of stock Nov 07
Less than half of directors are independent Oct 26
WuXi Biologics (Cayman) Inc. Provides Unaudited Consolidated Earnings Guidance for the Six Months Ended June 30, 2021 Jul 15
CEO & Executive Director recently sold Mex$88m worth of stock Jun 17 WuXi Biologics (Cayman) Inc. (SEHK:2269) completed the acquisition of Biologics manufacturing facilities in Hangzhou of Pfizer Investment Co. Ltd.
Full year 2020 earnings released: EPS CN¥0.43 (vs CN¥0.27 in FY 2019) May 01
Insider recently bought Mex$9.2m worth of stock Mar 31
Full year 2020 earnings released: EPS CN¥0.43 (vs CN¥0.27 in FY 2019) Mar 25
WuXi Biologics (Cayman) Inc. (SEHK:2269) agreed to acquire a 90% stake in CMAB Biopharma Inc. from CBC Group. Mar 19
WuXi Biologics (Cayman) Inc. (SEHK:2269) entered into an equity agreement to acquire Biologics manufacturing facilities in Hangzhou of Pfizer Investment Co. Ltd. Mar 17
Exelixis, Inc. Enters into License Agreement with WuXi Biologics to Support Further Expansion of its Growing Oncology Biologics Pipeline Mar 10
Wuxi Biologics (Cayman) Inc. Receives Remote Pre-Approval Inspection by European Medicines Agency on MFG4 Facility Mar 04
WuXi Biologics (Cayman) Inc. to Report Fiscal Year 2020 Results on Mar 23, 2021 Feb 27
Antengene Corporation Limited Announces Collaboration with WuXi Biologics and WuXi STA to Advance Antibody-Drug Conjugate Candidate into Clinical-stage Feb 01
Executive VP recently sold Mex$275m worth of stock Jan 28
Oxford BioTherapeutics Ltd Designates Second Bispecific Antibody Program Leveraging Wuxi Biologics’ Wuxibody® Platform Jan 21
Oxford BioTherapeutics Designates Second Bispecific Antibody Program Leveraging WuXi Biologics’ WuXiBody® Platform Jan 20
WuXi Biologics Receives GMP Certification from Brazil's ANVISA Dec 29 주주 수익률 2269 N MX Life Sciences MX 마켓 7D 0% 0% 0% 1Y n/a 0% 0%
전체 주주 수익률 보기
수익률 대 산업: MX Life Sciences 산업에 대해 2269 N 의 성과를 판단하기에는 데이터가 부족합니다.
수익률 대 시장: MX 시장에 대해 2269 N 의 성과를 판단하기에는 데이터가 부족합니다.
가격 변동성 Is 2269 N's price volatile compared to industry and market? 2269 N volatility 2269 N Average Weekly Movement n/a Life Sciences Industry Average Movement 0% Market Average Movement 0% 10% most volatile stocks in MX Market 0% 10% least volatile stocks in MX Market 0%
안정적인 주가: 2269 N 지난 3개월 동안 MX 시장에 비해 상당한 가격 변동성이 발생하지 않았습니다.
시간에 따른 변동성: 지난 1년간 2269 N 의 변동성 변화를 확인하기에는 데이터가 충분하지 않습니다 .
WuXi Biologics (Cayman) Inc. 기본 사항 요약 WuXi Biologics (Cayman) 의 수익과 매출은 시가총액과 어떻게 비교하나요? 2269 N 기본 통계 시가총액 Mex$132.67b 수익(TTM ) Mex$9.71b 수익(TTM ) Mex$38.71b
수익 및 수익 최신 수익 보고서의 주요 수익성 통계(TTM) 2269 N 손익 계산서(TTM ) 수익 CN¥16.55b 수익 비용 CN¥9.68b 총 이익 CN¥6.87b 기타 비용 CN¥2.72b 수익 CN¥4.15b
주당 순이익(EPS) 0.99 총 마진 41.51% 순이익 마진 25.08% 부채/자본 비율 7.7%
2269 N 의 장기적인 성과는 어땠나요?
과거 실적 및 비교 보기
기업 분석 및 재무 데이터 현황 데이터 마지막 업데이트(UTC 시간) 기업 분석 2024/03/18 14:15 장 마감 주가 2023/12/20 00:00 수익 2023/06/30 연간 수익 2022/12/31
데이터 소스 기업 분석에 사용된 데이터는 S&P Global Market Intelligence LLC의 데이터입니다. 이 보고서를 생성하기 위해 분석 모델에 사용된 데이터는 다음과 같습니다. 데이터는 정규화되어 있으므로 소스가 제공되기까지 지연이 발생할 수 있습니다.
패키지 데이터 기간 미국 소스 예시 * 회사 재무 10년 애널리스트 컨센서스 추정치 +3년 시장 가격 30년 소유권 10년 관리 10년 주요 개발 사항 10년
* 미국 증권의 경우, 미국 외 지역의 규제 양식 및 출처는 미국 증권의 예를 사용했습니다.
명시되지 않는 한 모든 재무 데이터는 1년을 기준으로 하지만 분기별로 업데이트됩니다. 이를 후행 12개월(TTM) 또는 최근 12개월(LTM) 데이터라고 합니다. 자세히 알아보기 .
분석 모델 및 눈송이 이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 Github 페이지에서 확인할 수 있으며, 보고서 사용 방법에 대한 가이드와 튜토리얼도 유튜브에서 확인할 수 있습니다.
Simply 월스트리트 분석 모델을 설계하고 구축한 세계적인 수준의 팀에 대해 알아보세요.
산업 및 부문 메트릭 업계 및 섹션 지표는 Simply Wall St에서 6시간마다 계산되며, 자세한 내용은 Github에서 확인할 수 있습니다.
애널리스트 출처 WuXi Biologics (Cayman) Inc. 56 애널리스트 중 32 애널리스트가 보고서의 입력 자료로 사용된 매출 또는 수익 추정치를 제출했습니다. 애널리스트의 제출 자료는 하루 종일 업데이트됩니다.
분석가 교육기관 Wai Chak Yuen BOCI Research Ltd. Linda Lu BOCI Research Ltd. Bo Li BofA Global Research
53 더 많은 분석가 보기 